Career CategoryMarketing Job Description 職務内容： 肺がん領域におけるビジネス最大化に向けリードプロダクトマネージャーと協働した製品戦略の立案 戦略立案を基軸とし肺がん領域ビジネスの成長に向けた各種プランニングとレビュー機会（BPF: Brand Plan Framework）等のプロジェクトマネジメント業務 職務責任： Excel等を活用して各種データソース（対象市場の各種製品売上実績、市場調査など）を用いた環境分析業務を担う 肺がん製品戦略および戦術実行に関する部門横断的な各種タスクの総合進捗管理をリードする 戦術プランのリードを担うBE（ブランドエンゲージメント）関係者と緊密に連携し戦術の立案/準備を協働する メディカル部門を含む各種連携部門関係者との定期的な議論を通じ「To Serve Patients」を実現するためのマーケティング施策の向上を図る 検討を進める戦略/戦術の実展開に向けてオンコロジー事業部営業部門との強固な連携を図るべく議論の先導役を担う 固形がん領域マーケティング Associate Directorへダイレクトレポートする 応募条件： 3年以上の固形がん領域（特に肺がん領域）におけるプロダクトマーケティング業務従事経験を有する Excelフォーマットを活用した各種データ分析スキルを有する チームや組織のために率先垂範で行動でき、高いコミュニケーションスキルを有する コンプライアンスを遵守し正しい倫理観をもって行動し説明責任を果たすことができる 困難に直面した際、目標達成に向けて粘り強く行動し続ける（Resilience） 環境変化下にあって、状況を的確に捉え柔軟かつ迅速に対応できる（Agility） 営業組織や営業支援組織と効果的な連携と協働、そして必要に応じてこちらから戦略的かつ主体的な提案ができる ビジネスレベルの英語によるコミュニケーションスキル（英語による文書作成および会議、ディスカッション、プレゼンテーションを実施できる） ....
Senior Scientific Expert (GU Oncology or Lung Cancer) YOUR TASKS AND RESPONSIBILITIES: Lead Medical strategy and execution for the therapeutic area, with clear priorities and measurable outcomes. Provide Japanese Medical input into clinical development, target product profiles,
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
MAIN REPONSIBILITIES / DUTIES JOB POSITION PURPOSE The MAS roles are hybrid in responsibilities. Specific roles in teams can vary between 80% field with 20% head office activity to 80% head office activity with 20% field
Work ScheduleStandard (Mon-Fri) Environmental ConditionsOffice Job DescriptionAs part of the Thermo Fisher Scientific team, you’ll discover meaningful work that makes a positive impact on a global scale. Join our colleagues in bringing our Mission to life
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Job Purpose The Head of Disease Area (DA), Oncology Medical is a key leadership role responsible for building, developing, and leading a DA team within Japan Oncology Medical. This role provides strategic and operational leadership across
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
At Gilead, we’re creating a healthier world for all people. For more than 35 years, we’ve tackled diseases such as HIV, viral hepatitis, COVID-19 and cancer – working relentlessly to develop therapies that help improve lives and
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of